SAGE Therapeutics Inc
NASDAQ:SAGE
SAGE Therapeutics Inc
Research & Development
SAGE Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SAGE Therapeutics Inc
NASDAQ:SAGE
|
Research & Development
-$138.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
SAGE Therapeutics Inc
Glance View
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2014-07-18. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.
See Also
What is SAGE Therapeutics Inc's Research & Development?
Research & Development
-138.3m
USD
Based on the financial report for Jun 30, 2025, SAGE Therapeutics Inc's Research & Development amounts to -138.3m USD.
What is SAGE Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-11%
Over the last year, the Research & Development growth was 54%. The average annual Research & Development growth rates for SAGE Therapeutics Inc have been 24% over the past three years , 16% over the past five years , and -11% over the past ten years .
